Spanish Menopause Society position statement: Use of denosumab in postmenopausal women |
| |
| Authors: | Antonio Cano,José Manuel Silvan,Antonio Esté vez,Francesc Baró ,José Villero,Francisco Quereda,Javier Ferrer,Nicolá s Mendoza,Rafael Sá nchez-Borrego |
| |
| Affiliation: | 1. Hospital Universitario Dr Peset, University of Valencia, Valencia, Spain;2. Hospital Universitario Virgen del Rocío, University of Seville, Seville, Spain;3. Hospital Universitario de Valme, Seville, Spain;4. Hospital Vall d?Hebron, University of Barcelone, Barcelone, Spain;5. Hospital Reina Sofía, Córdoba, Spain;6. Hospital Universitario San Juan, Alicante, University Miguel Hernández, Alicante, Spain;g Hospital Universitario Central de Asturias, University of Oviedo, Spain;h Clinica Margen, Department of Obstetrics and Gynecology, University of Granada, Granada, Spain;i Clínica Diatros, Barcelone, Spain |
| |
| Abstract: | Denosumab is a new drug developed for the treatment of osteoporosis. Moreover, increasing evidences link denosumab with benefits in cancer, an area of interest for those in charge of the postmenopausal health. Denosumab has shown efficacy in the control of bone loss associated with hypogonadic states created by chemotherapy in breast and other cancers. Moreover, some studies reveal efficacy in reducing the progression of metastases. A panel of experts from the Spanish Menopause Society has met to develop usage recommendations based on the best available evidence. |
| |
| Keywords: | Denosumab Postmenopausal osteoporosis Breast cancer |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
